Los Angeles Capital Management & Equity Research Inc. owned approximately 0.22% of Boston Scientific Corporation worth $87,467,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its position in Boston Scientific Corporation by 157.3% in the 2nd quarter. Winslow Capital Management LLC now owns 11,212,783 shares of the medical equipment provider's stock valued at $310,818,000 after buying an additional 2,011,640 shares during the period. Arizona State Retirement System now owns 365,656 shares of the company's stock worth $6,878,000 after buying an additional 9,600 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Boston Scientific Corporation by 2.8% in the second quarter.
Boston Scientific Corporation is maintained at an average outperform rating by 24 stock analysts, and there are at least 1.01% of shares outstanding that are now legally short sold. Finally, Canaccord Genuity initiated coverage on shares of Boston Scientific Corporation in a research report on Tuesday, October 24th. After a recent check, the 14-day RSIfor Boston Scientific Corp (BSX) is now at 47.16, the 7-day stands at 51.24, and the 3-day is sitting at 62.61.
TRADEMARK VIOLATION NOTICE: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. The correct version of this news story can be read at https://weekherald.com/2017/11/14/toronto-dominion-bank-buys-56539-shares-of-boston-scientific-corporation-bsx.html. October 3 investment analysts at Needham & Company LLC made no change to the stock rating of "Buy" with a current price target of $32.00. On November 7 Royal Bank Of Canada held the stock rating at "Buy" projecting a price of $31.00. SunTrust Banks, Inc. set a $34.00 price objective on shares of Boston Scientific Corporation and gave the company a "buy" rating in a research report on Tuesday, October 31st. The consensus rating is 1.9, indicating analysts in general look favorably on the company's future prospects. The company has an average rating of Buy and a consensus target price of $25.43. Also, EVP Timothy A. Pratt sold 10,104 shares of the company's stock in a transaction on Friday, September 1st. The stock was sold at an average price of $27.46, for a total transaction of $277,455.84.
The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 5.99%, and has a solid year to date (YTD) performance of 31.53% which means that the stock is constantly adding to its value from the previous fiscal year end price. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The total value of its holdings increased 14.0%. The disclosure for this sale can be found here. The last close places the company's stock about $1.48 off its 52 week high of $29.93 and $8.78 above the 52 week low of $19.67. The stock traded within a range of $28.19 and $28.61. Over the past five trading sessions it is 2.3%; -3.36% for the month; 7.48% for the last quarter; 7.44% for the past six-months; and 32.33% for the last 12 months. On average, equities research analysts predict that Boston Scientific Corp. will post $1.10 earnings per share for the current year.
The company now has an insider ownership of 0.1 Percent and Institutional ownership of 94.2 Percent. The share price has yet to cross its 20 days moving average, floating at a distance of -1.36% and sits -1.56% lower versus its 50 days moving average.
Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. In the latest earnings report the EPS was $0.61 with 1.37B shares now outstanding.
Price-to-free-cash-flow (P/FCF) of 49.29 gives an overview of the equity valuation for Boston Scientific Corporation. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.21 billion. During the same period in the prior year, the company earned $0.27 EPS. A ratio under 1 points out that the company's liabilities are higher than its assets and indicates that the company may be unable to pay off its obligations when they fall short.
With today's market cap for Boston Scientific Corporation, traders can easily name it as one of the major player in its Medical Appliances & Equipment industry. The company's products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.